| http://www.w3.org/ns/prov#value | - ics and bioequivalence to Labopharm's existing once-daily tramadol product, while in vitro studies demonstrated a range of abuse- and misuse-deterrent characteristics.About Labopharm Inc.Headquartered in Laval, Canada with US offices in Princeton, New Jersey, Labopharm is an emerging leader in optimizing the performance of existing small molecule drugs using its proprietary controlled-release tech
|
